Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CDC25B | P30305 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | TPMT | P51580 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4278017 | 0.98 | MAPT (0.64) | MAPTTDP1ALDH1A1CDC25BKDM4E | |
| SCHEMBL9349731 | 0.85 | MAPT (0.61) | MAPTTDP1ALDH1A1CDC25BKDM4E | |
| SCHEMBL28324244 | 0.85 | MAPT (0.55) | MAPTTDP1ALDH1A1CDC25BKDM4E | |
| SCHEMBL3421092 | 0.84 | MAPT (0.50) | MAPTTDP1ALDH1A1KDM4EHTT | |
| SCHEMBL102827 | 0.82 | MAPT (0.72) | MAPTTDP1ALDH1A1CDC25BKDM4E | |
| SCHEMBL4278020 | 0.82 | MAPT (0.49) | MAPTTDP1ALDH1A1CA1CA2 | |
| SCHEMBL7467765 | 0.81 | TDP1 (0.47) | MAPTTDP1ALDH1A1KDM4EHPGD | |
| Water SCHEMBL9749470 | 0.81 | MAPT (0.70) | MAPTTDP1ALDH1A1CDC25BKDM4E | |
| Hydrochloric Acid SCHEMBL5061862 | 0.81 | MAPT (0.70) | MAPTTDP1ALDH1A1CDC25BKDM4E | |
| SCHEMBL27341170 | 0.81 | MAPT (0.70) | MAPTTDP1ALDH1A1CDC25BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455540-B2 | Gossypol and apogossypol derivatives, preparation thereof and uses thereof | UNIVERSITE DU MAINE (LE MANS) (FR) | 2013-06-04 | — | — | US | disclosed |
| US-20100331398-A1 | DERIVES DU GOSSYPOL ET DE L'APOGOSSYPOL, LEURS PREPARATIONS ET LEURS APPLICTIONS | UNIVERSITE DU MAINE (LE MANS) (FR) | 2010-12-30 | — | — | US | disclosed |
| CN-1191249-C | Quinoline and quinazoline compound for treating benign prostatic hyperplasia specially | PFIZER (US) | 2005-03-02 | — | — | CN | disclosed |
| US-6653302-B2 | Benign prostatic hyperplasia | PFIZER INC. | 2003-11-25 | — | — | US | disclosed |
| US-20030130259-A1 | Quinoline and quinazoline compounds useful in therapy | FOX DAVID NATHAN ABRAHAM (GB) | 2003-07-10 | — | — | US | disclosed |
| EP-0968208-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY, PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | PFIZER LTD (GB) | 2003-06-04 | — | — | EP | disclosed |
| CN-1403453-A | Quinoline and quinazoline compound for treating benign prostatic hyperplasia specially | PFIZER (US) | 2003-03-19 | — | — | CN | disclosed |
| US-6521629-B2 | 2-amine substituted quinoline or quinozoline derivatives useful for treating benign prostatic hyperplasia | PFIZER INC. | 2003-02-18 | — | — | US | disclosed |
| CN-1093858-C | Quinoline and quinazoline compounds for the treatment, in particular for the treatment of benign prostatic hyperplasia | PFIZER LTD (US) | 2002-11-06 | — | — | CN | disclosed |
| US-20020040028-A1 | Quinoline and quinazoline compounds useful in therapy | FOX DAVID NATHAN ABRAHAM (GB) | 2002-04-04 | — | — | US | disclosed |
| US-6365599-B1 | FOR THERAPY OF BENIGN PROSTATIC HYPERPLASIA | PFIZER, INC. | 2002-04-02 | — | — | US | disclosed |
| US-6169093-B1 | FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | PFIZER INC. | 2001-01-02 | — | — | US | disclosed |
| CN-1243513-A | Quinoline and quinazoline compounds for the treatment, in particular for the treatment of benign prostatic hyperplasia | PFIZER LTD (US) | 2000-02-02 | — | — | CN | disclosed |
| EP-0968208-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY, PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | Pfizer Limited (GB) | 2000-01-05 | — | — | EP | disclosed |
| WO-1998030560-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY, PARTICULARLY IN THE TREATMENT OF BEGNIN PROSTATIC HYPERPLASIA | PFIZER LIMITED (GB) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130259-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, LPXN | MAPT 3009/4885TDP1 1261/4885ALDH1A1 498/4885 |
| US-20020040028-A1 | Quinoline and quinazoline compounds useful in therapy | BPHL, LPXN, NQO2 | MAPT 2899/4885TDP1 1352/4885ALDH1A1 420/4885 |
| US-20100331398-A1 | DERIVES DU GOSSYPOL ET DE L'APOGOSSYPOL, LEURS PREPARATIONS ET LEURS APPLICTIONS | LSS, GRHPR, NR1H3 | MAPT 2563/4885TDP1 1282/4885ALDH1A1 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.